Experience and challenges from clinical trials with malaria vaccines in Africa

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Mwangoka, Grace ^a   Ogutu, Bernhards ^b   Msambichaka, Beverly ^a   Mzee, Tutu ^a   Salim, Nahya ^a   Kafuruki, Shubis ^a   Mpina, Maxmillian ^a   Shekalaghe, Seif ^a   Tanner, Marcel ^c   Abdulla, Salim ^a  

^a IFAKARA HEALTH INSTITUTE   (Tanzania)

^b Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Ghana)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Africa; Challenges; Clinical trials; Experiences; Malaria; Vaccines

Indexed keywords

IMMUNOGLOBULIN G; MALARIA VACCINE; ORAL POLIOMYELITIS VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AFRICA; ARTICLE; CD4+ T LYMPHOCYTE; DRUG EFFICACY; FOLLOW UP; GOOD CLINICAL PRACTICE; HUMAN; MALARIA; MALARIA CONTROL; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; RESEARCH ETHICS; TH1 CELL; VACCINATION;

AFRICA; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; MALARIA; MALARIA VACCINES; NEGLECTED DISEASES; TUBERCULOSIS;

EID: 84874446254     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-86     Document Type: Article

References (65)

1. WHO, World Malaria Report Geneva: World Health Organization 2010 http://www.who.int/malaria/world-malaria-report-2010/en/
2. Estimates of the burden of malaria morbidity in Africa in children under the age of 5years. Roca-Feltrer A, Carneiro I, Armstrong-Schellenberg JR, Trop Med Int Health 2008 13 771 783 10.1111/j.1365-3156.2008.02076.x 18363586 (Pubitemid 351678643)
3. Malaria in pregnancy and the newborn. Rogerson SJ, Adv Exp Med Biol 2010 659 139 152 10.1007/978-1-4419-0981-7-12 20204762
4. Malaria and pregnancy: A global health perspective. Schantz-Dunn J, Nour NM, Rev Obstet Gynecol 2009 2 186 192 19826576
5. A research agenda for malaria eradication: vaccines. The malERA Consultative Group on Vaccines, PLoS Med 2011 8 1000398 21311586
6. Malaria Vaccine Technology Roadmap Final Report 2006 http://www. malariavaccine.org/files/Malaria-Vaccine-TRM-Final-000.pdf
7. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, RTS,S Clinical Trials Partnership, N Engl J Med 2011 365 1863 1875 22007715
8. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, RTS, N Engl J Med 2012 367 2284 2295 23136909
9. WHO, Malaria Vaccine Rainbow Tables December 2012 http://www.who.int/ vaccine-research/links/Rainbow/en/index.html
10. Clinical development of malaria vaccines: should earlier trials be done in malaria endemic countries? Chilengi R, Hum Vaccin 2009 5 627 19617708
11. Malaria: deploying a candidate vaccine (RTS, S/AS02A) for an old scourge of humankind. Alonso PL, Int Microbiol 2006 9 83 93 16835838 (Pubitemid 44047820)
12. A review of human vaccine research and development: malaria. Girad MP, Reed ZH, Friede M, Kieny MP, Vaccine 2007 25 1567 1580 10.1016/j.vaccine.2006. 09.074 17045367 (Pubitemid 46108198)
13. Pre-erythrocytic malaria vaccines:towards greater efficacy. Hill AVS, Nat Rev Immunol 2006 6 21 32 10.1038/nri1746 16493425 (Pubitemid 43279750)
14. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Peduzzi E, Westerfeld N, Zurbriggen R, Pluschke G, Daubenberger CA, Clin Immunol 2008 127 188 197 10.1016/j.clim.2008.01.012 18337175
15. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Holder AA, Guevara Patino JA, Uthaipibull C, Syed SE, Ling IT, Scott-Finnigan T, Blackman MJ, Parassitologia 1999 41 409 414 10697894 (Pubitemid 129640287)
16. Antibodies in falciparum malaria: what matters most, quantity or quality? Bouharoun-Tayoun H Druilhe P, Mem Inst Oswaldo Cruz 87 Suppl 1992 3 229 234
17. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P, J Exp Med 1990 172 1633 1641 10.1084/jem.172.6.1633 2258697
18. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Perignon JL, Druilhe P, PLoS Med 2007 4 320 10.1371/journal.pmed.0040320 18001147 (Pubitemid 350220532)
19. Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Ndungu FM, Bull PC, Ross A, BS Lowe BS, Kabiru E, Marsh K, Parasite Immunol 2002 24 77 82 10.1046/j.0141-9838.2001.00440.x 11874562 (Pubitemid 34225276)
20. IgG1 and IgG2 antibody responses to Plasmodium falciparum exoantigens correlate inversely and positively, respectively, to the number of malaria attacks. Chumpitazi BF, Lepers JP, Simon J, Deloron P, FEMS Immunol Med Microbiol 1999 14 151 158
21. Immunologic responses to soluble exoantigens of Plasmodium falciparum in Gabonese children exposed to continuous intense infection. Luty AJ, Mayombo J, Lekoulou F, Mshana R, AmJTrop Med Hyg 1994 51 720 729
22. Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, Toure BA, Diatta B, Seignot P, Roussilhon C, Infect Immun 1997 65 3271 3276 9234786 (Pubitemid 27342410)
23. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Shi YP, Sayed U, Qari SH, Roberts JM, Udhayakumar V, Oloo AJ, Hawley WA, Kaslow DC, Nahlen BL, Lal AA, Infect Immun 1996 64 2716 2723 8698500 (Pubitemid 26226838)
24. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Taylor RR, Allen SJ, Greenwood BM, Riley EM, AmJTrop Med Hyg 1998 58 406 413 (Pubitemid 28183248)
25. Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Iriemenam NC, Khirelsied AH, Nasr A, ElGhazali G, Giha HA, Elhassan A-E, Agab-Aldour AA, Montgomery SM, Anders RF, Theisen M, Troye-Blomberg M, Elbashir MI, Berzins K, Vaccine 2009 27 62 71 10.1016/j.vaccine.2008.10.025 18977268
26. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, Konate AT, Chilengi R, Theisen M, Dodoo D, Remarque E, Bosomprah S, Milligan P, Sirima SB, Infect Immun 2008 76 759 766 10.1128/IAI.01147-07 18070896 (Pubitemid 351251748)
27. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. Ndungu FM, Mwacharo J, Kimani D, Kai O, Moris P, Jongert E, Vekemans J, Olotu A, Bejon P, PLoS One 2012 7 52870 10.1371/journal.pone.0052870 23300801
28. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG Jr, J Infect Dis 2009 200 337 346 10.1086/600120 19569965
29. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR, J Infect Dis 2001 183 640 647 10.1086/318534 11170991 (Pubitemid 32147521)
30. Insights into long-lasting protection induced by RTS, S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. Guinovart C, Aponte JJ, Sacarlal J, Aide P, Leach A, Bassat Q, Macete E, Dobaño C, Lievens M, Loucq C, Ballou WR, Cohen J, Alonso PL, PLoS One 2009 4 5165 10.1371/journal.pone.0005165 19365567
31. Circumsporozoite-specific T cell responses in children vaccinated with RTS, S/AS01E and protection against P. falciparum clinical malaria. Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, Kai O, Jongert E, Lievens M, Leach A, Villafana T, Savarese B, Marsh K, Cohen J, Bejon P, PLoS One 2011 6 25786 10.1371/journal.pone.0025786 21998698
32. Safety and efficacy of the RTS, S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19month follow-up of a randomised, open-label, phase 2 trial. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, Salim N, Fernandes JF, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Moller T, Apanga S, Mwangoka G, Dubois MC, Madi T, Kwara E, Minja R, Hounkpatin AB, Boahen O, Kayan K, Adjei G, Chandramohan D, Carter T, Lancet Infect Dis 2011 11 741 749 10.1016/S1473-3099(11)70100-1 21782519
33. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J, Lancet 2004 364 1411 1420 10.1016/S0140-6736(04)17223-1 15488216 (Pubitemid 39370716)
34. The RTS, S malaria vaccine. Casares S, Brumeanu TD, Richie TL, Vaccine 2010 28 4880 4888 10.1016/j.vaccine.2010.05.033 20553771
35. A vaccine for malaria. White NJ, N Engl J Med 2011 365 1926 1928 10.1056/NEJMe1111777 22007716
36. A review of malaria vaccine clinical projects based on the WHO rainbow table. Schwartz L, Brown GV, Genton B, Moorthy VS, Malar J 2012 11 11 10.1186/1475-2875-11-11 22230255
37. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, Dunachie S, Andrews L, Williams JL, Sinden R, Gilbert SC, Pluschke G, Zurbriggen R, Hill AV, PLoS One 2008 3 1493 10.1371/journal.pone.0001493 18231580 (Pubitemid 351827205)
38. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. Cech PG, Aebi T, Abdallah MS, Mpina M, Machunda EB, Westerfeld N, Stoffel SA, Zurbriggen R, Pluschke G, Tanner M, Daubenberger C, Genton B, Abdulla S, PLoS One 2011 6 22273 10.1371/journal.pone.0022273 21799810
39. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BK, Hum Vaccin 2010 6 97 106 10.4161/hv.6.1.10396 19946222
40. Protection against a malaria challenge by sporozoite inoculation. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, Teelen K, Arens T, Spaarman L, Roeffen W, Snounou G, Renia L, Hermsen CC, Sauerwein R, d van V, N Engl J Med 2009 361 468 477 10.1056/NEJMoa0805832 19641203
41. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW, Lancet 2011 377 1770 1776 10.1016/S0140-6736(11)60360-7 21514658
42. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A, Malar J 2007 6 107 10.1186/1475-2875-6-107 17686163 (Pubitemid 350103125)
43. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Moorthy V, Reed Z, Smith PG, Vaccine 2007 25 5115 5123 10.1016/j.vaccine.2007.01.085 17577487 (Pubitemid 46915464)
44. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P, Greenwood B, Ofori-Anyinam O, Okech B, Villafana T, Carter T, Savarese B, Duse A, Reijman A, Ingram C, Frean J, Ogutu B, Malar J 2011 10 223 10.1186/1475-2875-10-223 21816032
45. Attributable fraction estimates and case definitions for malaria in endemic areas. Smith T, Schellenberg JA, Hayes R, Stat Med 1994 13 2345 2358 10.1002/sim.4780132206 7855468 (Pubitemid 24354857)
46. Operational strategies to achieve and maintain malaria elimination. Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, Abeyasinghe RR, Rodriguez MH, Maharaj R, Tanner M, Targett G, Lancet 2010 376 1592 1603 10.1016/S0140-6736(10)61269-X 21035841
47. A research agenda to underpin malaria eradication. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, MM Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M, PLoS Med 2011 8 1000406 10.1371/journal.pmed.1000406 21311579
48. Relationships between the outcome of Plasmodium falciparum infection and the intensity of transmission in Africa. Smith T, Killeen G, Lengeler C, Tanner M, AmJTrop Med Hyg 2004 71 80 86 (Pubitemid 39121307)
49. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, Molineaux L, Tanner M, AmJTrop Med Hyg 2006 75 11 18
50. Quality improvement in the developing world. Smits HL, Leatherman S, Berwick DM, Int J Qual Health Care 2002 14 439 440 10.1093/intqhc/14.6.439 12515329 (Pubitemid 36054416)
51. Attrition in geriatric research: how important is it and how should it be dealt with? Gardette V, Coley N, Toulza O, Andrieu S, J Nutr Health Aging 2007 11 265 268 17508106
52. Recruitment and retention of Latinos in a primary care-based physical activity and diet trial: The Resources for Health study. Eakin, Bull SS, Riley K,Reeves MM, Gutierrez S, McLaughlin P, Health Educ Res 2007 22 361 371 16963726 (Pubitemid 47355772)
53. Global voices of science. It takes a village: medical research and ethics in Mali. Doumbo OK, Science 2005 307 679 681 10.1126/science.1109773 15692036 (Pubitemid 40194625)
54. Community permission for medical research in developing countries. Diallo DA, Doumbo OK, Plowe CV, Wellems TE, Emanuel EJ, Hurst SA, Clin Infect Dis 2005 41 255 259 10.1086/430707 15983925 (Pubitemid 40962509)
55. Valid consent for genomic epidemiology in developing countries. Chokshi DA, Thera MA, Parker M, Diakite M, Makani J, Kwiatkowski DP, Doumbo OK, PLoS Med 2007 4 95 10.1371/journal.pmed.0040095 17455985 (Pubitemid 46658765)
56. Grand challenges in global health: community engagement in research in developing countries. Tindana PO, Singh JA, Tracy CS, Upshur RE, Daar AS, Singer PA, Frohlich J, Lavery JV, PLoS Med 2007 4 273 10.1371/journal.pmed.0040273 17850178 (Pubitemid 47503036)
57. Challenges of establishing a Community Advisory Board (CAB) in a low-income, low-resource setting: experiences from Bagamoyo. Tanzania. Shubis K, Juma O, Sharifu R, Burgess B, Abdulla S, Health Res Policy Syst 2009 7 16 10.1186/1478-4505-7-16 19534798
58. Safety and Immunogenicity of 30 and 100 ìg of GMZ2 in Gabonese Children Aged 1-5 Years http://clinicaltrials.gov/ct2/show/NCT00703066 23211622
59. Engaging diverse communities participating in clinical trials: case examples from across Africa. Nyika A, Chilengi R, Ishengoma D, Mtenga S, Thera MA, Sissoko MS, Lusingu J, Tiono AB, Doumbo O, Sirima SB, Lemnge M, Kilama WL, Malar J 2010 9 86 10.1186/1475-2875-9-86 20346126
60. Ifakara Health Institute (IHI) http://www.ihi.or.tz
61. New Malaria Clinical Trial Site Inaugurated at Bagamoyo Tanzania http://www.mmv.org/newsroom/news/new-malaria-clinical-trial-site-inaugurated- bagamoyo-tanzania
62. Malaria Clinical Trial Site Inaugurated at Bagamoyo Tanzania 2009 http://www.mmv.org/newsroom/news
63. Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. Lang TA, White NJ, Tran HT, Farrar JJ, Day NP, Fitzpatrick R, Angus BJ, Denis E, Merson L, Cheah PY, Chilengi R, Kimutai R, Marsh K, PLoS Negl Tro. Dis 2010 4 619 10.1371/journal.pntd.0000619
64. European and Developing Countries Clinical Trials Partnership (EDCTP) http://www.edctp.org/uploads/tx-viprojects/Project-Profile-CB-Ethics-COHRED- 41303-Carel-IJsselmuiden.pdf
65. Novartis Annual Report 2009 http://www.novartis.pt/downloads/imprensa/ publicacoes/en/Novartis-Annual-Report-2009-EN.pdf